Citations (24)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Yanxian Hu, Zhaoyu Wang, Xin Huang, Bijun Xia, Lan Tang, Zhijie Zheng & Ling Ye. (2017) Oxidative metabolism of koumine is mainly catalyzed by microsomal CYP3A4/3A5. Xenobiotica 47:7, pages 584-591.
Read now
Read now
Lyubomir A Dourmishev & Assen L Dourmishev. (2008) Activity of certain drugs in inducing of inflammatory myopathies with cutaneous manifestations. Expert Opinion on Drug Safety 7:4, pages 421-433.
Read now
Read now
Articles from other publishers (22)
Amirhossein Sahebkar, Arrigo F.G. Cicero, Paolo Di Giosia, Irene Pomilio, Cosimo Andrea Stamerra, Paolo Giorgini, Claudio Ferri, Stephan Haehling, Maciej Banach & Tannaz Jamialahmadi. (2020) Pathophysiological mechanisms of statin‐associated myopathies: possible role of the ubiquitin‐proteasome system. Journal of Cachexia, Sarcopenia and Muscle 11:5, pages 1177-1186.
Crossref
Crossref
Ying Jiang, Zichao Yang, Lishun Zhang, Ruohong Yan, Siming Liu, Haikui Yang, Shanhe Wan, Zhonghuang Li, Zhengguang Zhu, Ling Ye & Jiajie Zhang. (2020) The cytochrome P450 metabolic profiling of SMU-B in vitro, a novel small molecule tyrosine kinase inhibitor. Journal of Pharmaceutical and Biomedical Analysis 188, pages 113400.
Crossref
Crossref
Ming-Ming Yan, Shu-Shan Wu, Yin-Qing Ying, Nan Lu & Ming-Kang Zhong. (2018) Safety assessment of concurrent statin treatment and evaluation of drug interactions in China. SAGE Open Medicine 6, pages 205031211879827.
Crossref
Crossref
Kevin D.J. O’Connor & Frank L. Mastaglia. 2014. Aminoff's Neurology and General Medicine. Aminoff's Neurology and General Medicine
685
711
.
Ameet Bakhai, Una Rigney, Samuel Hollis & Cathy Emmas. (2012) Co-administration of statins with cytochrome P450 3A4 inhibitors in a UK primary care population. Pharmacoepidemiology and Drug Safety 21:5, pages 485-493.
Crossref
Crossref
Russell A. Wilke, Melissa Antonik, Elenita I. Kanin, QiPing Feng & Ronald M. Krauss. 2012. Principles of Pharmacogenetics and Pharmacogenomics. Principles of Pharmacogenetics and Pharmacogenomics
125
135
.
Stephen Frohlich, Tom Ryan & Carl Fagan. (2011) Statin Therapy Associated with Fatal Rhabdomyolysis. Journal of the Intensive Care Society 12:1, pages 40-42.
Crossref
Crossref
John Brick. 2009. Wiley Encyclopedia of Forensic Science. Wiley Encyclopedia of Forensic Science.
John Brick. 2009. Wiley Encyclopedia of Forensic Science. Wiley Encyclopedia of Forensic Science.
Eileen E. Ming, Michael H. Davidson, Sanjay K. Gandhi, Marcelo Marotti, Carolyn G. Miles, Xiongkan Ke & James M. McKenney. (2008) Concomitant use of statins and CYP3A4 inhibitors in administrative claims and electronic medical records databases. Journal of Clinical Lipidology 2:6, pages 453-463.
Crossref
Crossref
Frank L. Mastaglia. 2008. Neurology and General Medicine. Neurology and General Medicine
695
719
.
Russell A. Wilke, Debbie W. Lin, Dan M. Roden, Paul B. Watkins, David Flockhart, Issam Zineh, Kathleen M. Giacomini & Ronald M. Krauss. (2007) Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nature Reviews Drug Discovery 6:11, pages 904-916.
Crossref
Crossref
S W Seto, A L S Au, T Y Lam, S S C Chim, S M Y Lee, S Wan, D C S Tjiu, N Shigemura, A P C Yim, S W Chan, S K W Tsui, G P H Leung & Y W Kwan. (2007)
Modulation by simvastatin of iberiotoxin-sensitive, Ca
2+
-activated K
+
channels of porcine coronary artery smooth muscle cells
. British Journal of Pharmacology 151:7, pages 987-997.
Crossref
Crossref
Robin Ali & Karen P. Alexander. (2007) Statins for the primary prevention of cardiovascular events in older adults: A review of the evidence. The American Journal of Geriatric Pharmacotherapy 5:1, pages 52-63.
Crossref
Crossref
Russell A Wilke. (2006)
Translational pharmacogenetics and risk management in the cardiovascular arena:
CYP3A5*3
model for gene-based drug selection
. Personalized Medicine 3:4, pages 385-390.
Crossref
Crossref
Rohit AroraMax Liebo & Frank Maldonado. (2016) Statin-Induced Myopathy: The Two Faces of Janus. Journal of Cardiovascular Pharmacology and Therapeutics 11:2, pages 105-112.
Crossref
Crossref
Russell A WilkeA Kenneth Musana & Wendell W Weber. (2005) Cytochrome P450 gene-based drug prescribing and factors impacting translation into routine clinical practice. Personalized Medicine 2:3, pages 213-224.
Crossref
Crossref
Joseph Trieu, Louise Emmett, Chandi Perera, Krish Thanakrishnan & Hans Van Der Wall. (2004) Rhabdomyolysis Resulting From Interaction of Simvastatin and Clarithromycin Demonstrated by Tc-99m MDP Scintigraphy. Clinical Nuclear Medicine 29:12, pages 803-804.
Crossref
Crossref
Carl J. VaughanAntonio M. GottoJrJr. (2004) Update on Statins: 2003. Circulation 110:7, pages 886-892.
Crossref
Crossref
J.A. Martínez Matos. (2003) Aumento de la actividad de la creatincinasa y miopatía por estatinas. Clínica e Investigación en Arteriosclerosis 15:4, pages 167-168.
Crossref
Crossref
Domenic A. Sica & Todd W.B. Gehr. (2002) 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and rhabdomyolysis: considerations in the renal failure patient. Current Opinion in Nephrology and Hypertension 11:2, pages 123-133.
Crossref
Crossref
Domenic A. Sica & Todd W.B. Gehr. (2007) Rhabdomyolysis and Satin Therapy: Relevance to the Elderly. The American Journal of Geriatric Cardiology 11:1, pages 48-55.
Crossref
Crossref